Refereed Publications

  1. Reece PA. Treatment options for H5N1: Lessons learned from the H1N1 pandemic. Postgrad Med 122(5):134-141 (2010).

  2. Reece PA. Zanamivir for the treatment of avian influenza (H5N1) infections in humans. Expert Rev Clin Pharmacol 3(1):25-29 (2010).

  3. Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol  79:1577-1586 (2007).

  4. Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA.  In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother 48(5):1766-1772 (2004).

  5. Macdonald SJ, Watson KG, Cameron R, Chalmers DK, Demaine DA, Fenton RJ, Gower D, Hamblin JN, Hamilton S, Hart GJ, Inglis GG, Jin B, Jones HT, McConnell DB, Mason AM, Nguyen V, Owens IJ, Parry N, Reece PA, Shanahan SE, Smith D, Wu WY, Tucker SP.  Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob Agents Chemother 48(12):4542-4549 (2004).

  6. McKimm-Breschkin JL, Colman PM, Jin B, Krippner GY, McDonald M, Reece PA, Tucker SP, Waddington L, Watson KG, Wu WY.  Tethered neuraminidase inhibitors that bind an influenza virus: A first step towards a diagnostic method for influenza.  Angew Chem Int Ed Engl 42(27):3118-3121 (2003).

  7. Watson KG, Brown RN, Cameron R, Chalmers DK, Hamilton S, Jin B, Krippner GY, Luttick A, McConnell DB, Reece PA, Ryan J, Stanislowski P, Tucker SP, Wu WY, Barnard DL, Sidwell RW.  An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.  J Med Chem 46(15):3181-3184 (2003).

  8. Begg EJ, Robson RA, Gardiner SJ, Hudson LJ, Reece PA, Olson SC, Sedman AJ.  Quinapril and its metabolite quinaprilat in human milk.  Br J Clin Pharmacol 51(5):478-481 (2001).

  9. Allen E, Tsanaclis LM, Wroe SJ, Reece PA, Sedman AJ.  Gabapentin does not affect antipyrine clearance.  J Clin Pharmacol 39:934-935 (1999).

  10. Forgue ST, Reece PA, Sedman AJ, deVries TM.  Inhibition of tacrine oral clearance by cimetidine.  Clin Pharmacol Ther 59(4):444-449 (1996).

  11. Sramek, JJ, Sedman AJ, Reece PA, Hourani J, Bockbrader H, Cutler NR.  Safety and tolerability of CI-979 in patients with Alzheimer's disease.  Life Sciences 57(5):503-510 (1995).

  12. Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A.  Effect of CI-988 on cholecystokinin tetra-peptide induced panic symptoms in healthy volunteers.  Biol Psychiatry 38(11):742-746 (1995).

  13. Reece PA, Garnett WR, Rock WL, Taylor JR, Underwood B, Sedman AJ, Rajagopalan R.  Lack of effect of tacrine administration on the anticoagulant activity of warfarin.  J Clin Pharmacol 35:526-528 (1995).

  14. Blum RA; Comstock TJ; Sica DA; Schultz RW; Keller E; Reetze P; Bockbrader H; Tuerck D; Busch JA; Reece PA; et al.  Pharmacokinetics of gabapentin in subjects with various degrees of renal function.  Clin Pharmacol Ther 56(2):154-159 (1994).

  15. Reece PA, Sedman AJ, Rose S, Wright DS, Dawkins R.  Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans.  J Clin Pharmacol 34(11):1126-1132 (1994).

  16. Begg EJ, Robson RA, Ikram H, Richards AM, Bammert-Adams JA, Olson SC, Posvar EL, Reece PA, Sedman AJ.  The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure.  Br J clin Pharmac 37:302-304 (1994).

  17. Davis R, Raby C,  Callahan MJ, Lipinski W, Schwarz R, Dudley D, Lauffer D, Reece PA, Jaen J, Tecle H. Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease.  Progress in Brain Research 98:439-445 (1993).

  18. Olver IN, Reece PA, Bishop JF, Morris RG, Hillcoat BL and Guentert TW.  A Phase 1 Study of doxifluridine as a five-day stepped-dose continuous infusion.  Am J Clin Oncol 13 (4):308-311 (1990).

  19. Reece PA, Olver IN, Morris RG, Bishop JF, Guentert TW, Hill HS and Hillcoat BL.  Pharmacokinetic study of doxifluridine given by five-day stepped-dose infusion.  Cancer Chemother Pharmacol 25:274-278 (1990).

  20. Reece PA and Zacest R.  Hydralazine.  In:  FH Messerli (ed), Cardiovascular Drug Therapy,  WB Saunders, New York, 1990, pp 834-848.

  21. Reece PA, Stafford I, Davy M and Freeman S.  Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer. Cancer Chemother Pharmacol 24:256-260 (1989).

  22. Bishop JF, Raghavan D, Olver IN, Reece PA, Morris RG and Friedlander ML. A phase I study of trimetrexate (NSC 352 122) administered by 5 day continuous infusion.  Cancer Chemother Pharmacol 24:246-250 (1989).

  23. Morris RG, Dale BM, Green RM, Reece PA, Kotasek D, Saccoia LC and Sage RE.  Alteration in duxorubicin and duxorubicinol plasma concentrations with repeated courses to patients.  Therapeutic Drug Monitoring 11:380-383 (1989).

  24. Reece PA, Stafford I, Abbott RL, Anderson C, Denham J, Freeman S, Morris RG, Gill PG and Olweny CL.  Two versus twenty-four infusion of cisplatin: pharmacokinetic considerations.  J Clin Oncol 7:270-275 (1989).

  25. Reece PA, Hill HS, Green R G, Morris RG, Dale BM, Kotasek D and Sage RE.  Renal clearance and protein binding of melphalan in patients with cancer.  Cancer Chemother Pharmacol 22:348-352 (1988).

  26. Zacest R and Reece PA. Hydrallazine. In: WH Birkenhager and JL Reid, Handbook of Hypertension, Volume 5, Pharmacology of Hypertensive Drugs, Elsevier, Amsterdam, 1988, pages 341 - 381 (Review).

  27. Powis G, Reece PA, Ahmann DL and Ingle JN.  Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.  Cancer Chemother Pharmacol 20:219-222 (1987).

  28. Reece PA, Stafford I, Russell J, Khan M and Gill PG.  A model for ultrafilterable platinum disposition in patients treated with cisplatin. Cancer Chem Pharmacol 20:26-32 (1987).

  29. Reece PA, Bishop JF, Olver IN, Stafford I, Hillcoat BL and Morstyn G. Pharmacokinetics of carboplatin (CBDCA) in patients with small cell lung carcinoma.  Cancer Chemother Pharmacol 19:326-330 (1987).

  30. Reece PA, Morris RG, Bishop JF, Olver IN and Raghavan D. Pharmacokinetics of trimetrexate administered by five day continuous infusion to patients with advanced cancer.  Cancer Res 47:2996-2999 (1987).

  31. Reece PA, Stafford I, Davy M and Freeman S.  Disposition of unchanged cisplatin in patients with ovarian cancer.  Clin Pharmacol Ther 42:320-325 (1987).

  32. Reece PA, Dale BM, Morris RG, Kotasek D, Gee D, Rogerson S and Sage RE. Effect of L-leucine on oral melphalan kinetics in patients.  Cancer Chemother Pharmacol 20:256-258 (1987).

  33. Imhoff DM, Reece PA, Dimitriades E, Ward D and Bochner F.  Direct measurement of salicylphenolic glucuronide in human urine.  Ther Drug Monit 8:321-325 (1986).

  34. Reece PA, Stafford I, Russell J and Gill PG.  Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatinum to patients.  J Clin Oncol 4:1392-1398 (1986).

  35. Reece PA, Stafford I, Russell J, Khan M and Gill PG.  Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin.  Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.  J Clin Oncol 5:304-309 (1986).

  36. Reece PA, Kotasek D, Morris RG, Dale BM and Sage RE.  The effect of food on oral melphalan absorption.  Cancer Chemother Pharmacol 16:194-197 (1985).

  37. Reece PA, Cozamanis I, Russell J and Gill PG.  Nonlinear renal clearance of ultrafilterable platinum in patients treated with cisplatinum.  Cancer Chemother Pharmacol 15:295-299 (1985).

  38. Reece PA, Disney AP, Stafford I and Shastry JCM.  Prednisolone protein binding in renal transplant patients.  Brit J Clin Pharmacol 20:159-162 (1985).

  39. Reece PA, Cozamanis I and Zacest R.  The synthesis, formulation and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteers.  J Pharm Sci 74:193-196 (1985).

  40. Zacest R and Reece PA.  Hydrallazine.  In:  WH Birkenhager and JL Reid, Handbook of Hypertension Vol 5:  Pharmacology of Antihypertensive Drugs, Elsevier, Amsterdam, 1984 pp 312-349 (Review).

  41. Reece PA, McCall JT, Powis G and Richardson RL.  Sensitive high performance liquid chromatographic assay for platinum in plasma ultrafiltrate.  J Chromatogr 306:417-423 (1984).

  42. Morris RM and Reece PA.  Sensitive gas liquid chromatographic-nitrogen detection assay for fenfluramine and nor-fenfluramine in human plasma.  J Chromatogr 278:434-438 (1983).

  43. Zacest R and Reece PA.  Endralazine and sexual arousal.  Lancet, May 28, 1221 (1983) (Letter).

  44. Reece PA, Cozamanis I and Zacest R.  Endralazine - A new hydralazine-like antihypertensive with high systemic bioavailability.  Eur J Clin Pharmacol 25:553-556 (1983).

  45. Jones T, Reece PA and Sansom L.  Mexiletine removal in peritoneal dialysis.  Eur J Clin Pharmacol 25:839-840 (1983) (Letter).

  46. Zacest R and Reece PA.  I.V. Hydralazine.  Med J Aust June, 497-498 (1982).

  47. Reece PA, Cozamanis I and Zacest R.  Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.  Eur J Clin Pharmacol 23:523-527 (1982).

  48. Reece PA, Cozamanis I and Zacest R.  Pharmacokinetics of the vasodilators hydralazine and endralazine.  In:  LZ Benet and G Levy (eds), Pharmacokinetics, A Modern Via, Plenum, New York, 1982.

  49. Reece PA.  Hydralazine and related compounds - chemistry, mode of action and metabolism.  Medicinal Research Reviews 1:73-96 (1981) (Review).

  50. Reece PA.  The application of a fully automated high pressure liquid chromatography to multiple drug analyses.  Chromatography Review 7:14-15 (1981).

  51. Armarego WLF and Reece PA.  Quinazolines, XXV.  The synthesis of 2-(4-(2-furoyl)piperazin-l-yl)-8-chloro-6,7-dimethoxyquinazolin-4-ylamine hydrochloride (8-chloroprazosin hydrochloride).  Aust J Chem 34:1561-1566 (1981).

  52. Reece PA, Cozamanis I and Zacest R.  A sensitive assay for endralazine and two of its metabolites in human plasma.  J Chromatogr 225:151-160 (1981).

  53. Lane MJ, Reece PA and Schapel GJ.  Excessive frequency of phenytoin dosage.  Med J Aust 1:191-192 (1981) (Letter).

  54. Reece PA, Cozamanis I and Zacest R.  Selective HPLC assays for hydralazine and its metabolites in plasma of man.  J Chromatogr 181:427-440 (1980).

  55. Reece PA and Stanley PE.  High performance liquid chromatographic assay for tocainide in human plasma : comparison with gas-liquid chromatography.  J Chromatogr 183:109-114 (1980).

  56. Reece PA, Cosamanis I and Zacest R.  Pharmacokinetics of hydralazine and its main metabolites in slow and fast acetylators.  Clin Pharmacol Ther 28:769-780 (1980).

  57. Reece PA.  Quantification of prazosin in plasma by high performance liquid chromatography and fluorescence detection.  J Chromatogr 221:188-192 (1980).

  58. Schapel GJ, Beran RG, Doecke CJ, O'Reilly WJ, Reece PA, Rischbieth RHC, Sansom LN and Stanley PE.  Pharmacokinetics of sodium valproate in epileptic patients.  Eur J Clin Pharmacol 17:71-77 (1980).

  59. Reece PA and Peikert M.  A simple and selective HPLC method for estimating plasma quinidine levels.  J Chromatogr 181:207-217 (1980).

  60. Reece PA, Zacest R and Barrow G.  Determination of imipramine and desipramine in plasma by high pressure liquid chromatography.  J Chromatogr 163:310-314 (1979).

  61. Reece PA and Cozamanis I.  Injector loop sizes in high pressure liquid chromatography.  Chromatography Review 5:14-15 (1979).

  62. Reece PA;  Stanley PE and Zacest R. Interference in the assays of hydralazine in humans by a major plasma metabolite, hydralazine pyruvic acid hydrazone.  J Pharm Sci 67:1150-1153 (1978).

  63. Armarego WLF and Reece PA.  Purine Studies Part XX.  The methylation and reduction of 2,8-dioxo-2,8-diamino- and 2-amino-8-oxo-purines and the stereochemistry of their 1,4,5,6-tetrahydroderivatives.  J C S Perk I:1414-1424 (1976).

  64. Prager R and Reece PA. On the alkylation of alpha-bromo ketones by trialkylboranes.  Aust J Chem 28:1775-1783 (1975).

  65. Armarego WLF and Reece PA.  Two facile C4-N9 bond cleavages in purines and the methylation of 2,3,7,8-tetrahydro-2,8-dioxopurine.  Tet Letters, No. 6:423-424 (1975).

  66. Armarego WLF and Reece PA.  Quinazolines. Part XXI. Synthesis of cis-2-amino-8a- carboxymethyl-3,4,4a,5,5a,7,8,8a-octahydro-quinazolines. Conversation of perhydroquinazolin - 2 - ones into 2-amino-3,4,4a,5,6,7,8,8a-octahydroquinazolines.  J C S Perk I:1470-1474 (1975).

  67. Armarego WLF and Reece PA.  Quinazolines.  Part XX.  Synthesis and stereochemistry of N-methyl cis-perhydroquinazolin-2-ones; a new conformation for cisperhydroquinazolines.  J C S Perk I:2313-2319 (1974).

 

 

 
 
Preloaded imagePreloaded imagePreloaded imagePreloaded imagePreloaded imagePreloaded imagePreloaded imagePreloaded imagePreloaded imagePreloaded imagePreloaded imagePreloaded image
Close